Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

TitleGynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.
Publication TypeJournal Article
Year of Publication2014
AuthorsReed, NSimon, Gomez-Garcia, E, Gallardo-Rincon, D, Barrette, BA, Baumann, KH, Friedlander, MLeonard, Kichenadasse, G, Kim, J-W, Lorusso, D, Mirza, MRaza, Ray-Coquard, I
JournalInt J Gynecol Cancer
Issue9 Suppl 3
Date Published11/2014
KeywordsCarcinoid Tumor, Combined Modality Therapy, Consensus, Female, Humans, Medical Oncology, Ovarian Neoplasms, Practice Guidelines as Topic, Societies, Medical

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms most commonly occurring in the gastrointestinal tract or the lungs. More frequent are gastrointestinal tumors, but over the past 30 years, there have been a number of small series or anecdotal case reports on ovarian NETs. Neuroendocrine tumors in the gynecologic tract are uncommon and account for about 2% of all gynecologic malignancies but may also be metastatic from other sites. They require a multimodality therapeutic approach determined by the extent of disease and the primary organ of involvement. Pathological diagnosis is critical to guide therapy. Surgery is the cornerstone of treatment for localized disease. There have been many new developments for treatment of advanced NETs including somatostatin analogs, hepatic artery embolization, chemotherapy, interferons, mammalian target of rapamycin inhibitors and radiolabeled somatostatin analogs. Given the rarity and lack of level I evidence, this is by nature more of a guidance and recommendation for management of these rare tumors until we can mount international studies.

Alternate JournalInt. J. Gynecol. Cancer
PubMed ID25341578